Amphastar Pharmaceuticals, Inc. (AMPH) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Drug Manufacturers - Specialty & Generic) last closed at $25.43. The rating moved from Overbought to Oversold on October 1, 2026.

• Public ratingOversold (as of October 3, 2026)
• Last close$25.43
• Last changeMoved from Overbought to Oversold on October 1, 2026
• SectorHealthcare
• IndustryDrug Manufacturers - Specialty & Generic

See all oversold Healthcare stocks →

AI analysis

Amphastar Pharmaceuticals, Inc. (AMPH) presents a cash‑generating profile anchored in sterile injectables and generics with defensive investor interest amid a risk‑off market. The company’s manufacturing footprint and existing contracts support near‑term stability, but broad policy headwinds around Medicare drug pricing, competitive pressures, and potential regulatory/manufacturing risks limit clear upside. Absent company-specific catalysts (new contracts, margin improvement, or product launches), expect range‑bound performance over the coming month with upside tied to operational wins or a reduction in payer pricing risk.

Key factors

• Stable revenue base from sterile injectables and generic portfolio that supports cash generation and operating stability
• Defensive sector flows amid recent risk-off market tone could provide near-term demand/support for healthcare names
• Material downside pressure from Medicare drug‑price negotiation and payer reimbursement trends that can compress pricing and margins
• Manufacturing capabilities and established supply contracts are a competitive advantage if regulatory/quality standards are maintained
• Limited company-specific catalysts in the near term and light volume environment increase directional uncertainty
• Potential upside from contract manufacturing or specialty injectable demand if the company wins new commercial supply agreements

Risks

• Ongoing Medicare/IRA pricing negotiations and broader payer pressure that could force lower ASPs and reduce revenues
• Regulatory or FDA inspection issues at manufacturing sites leading to production interruptions or remediation costs
• Heightened competition from branded players, generics, and new combination therapies that erode market share
• Supply‑chain disruptions or cost inflation that compress margins and increase working capital needs
• Litigation, product liability or recall events that can create outsized financial and reputational impact
• Macro risk‑off market swings and low trading volumes that amplify short‑term price volatility

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.